Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Oral JAK inhibitor makes headway in alopecia areata
Patients with severe alopecia areata (patchy baldness) had a dramatic hair regrowth, without serious adverse events, when treated with an investigational Janus kinase (JAK) inhibitor in the phase III THRIVE-AA2 study presented at AAD 2023.
Oral JAK inhibitor makes headway in alopecia areata
05 Apr 2023QUARTZ3 data make a case for using ivarmacitinib in atopic dermatitis
Treatment with the oral highly selective JAK1 inhibitor ivarmacitinib appears to help reduce disease activity in patients with moderate-to-severe atopic dermatitis (AD), with up to 42 percent of them having complete or near-complete clearance of involved skin areas, according to the results of the pivotal phase III QUARTZ3 trial presented at AAD 2023.
QUARTZ3 data make a case for using ivarmacitinib in atopic dermatitis
04 Apr 2023Online telepharmacy service delivers despite pandemic-related restrictions
A free online telepharmacy service, developed in the Philippines during the COVID-19 pandemic, may be used to provide and simplify medication information as part of primary care, reports a study.
Online telepharmacy service delivers despite pandemic-related restrictions
04 Apr 2023Study supports apixaban use in AF patients with dementia
Anticoagulation therapy with apixaban yields lower rates of ischaemic stroke and intracranial and extracranial major bleeding compared with other oral anticoagulants (OACs) in patients with atrial fibrillation (AF), with the magnitude of benefit for major bleeding even greater for those who have dementia, according to a study.
Study supports apixaban use in AF patients with dementia
04 Apr 2023Tumour immune barrier determines immunotherapy efficacy in HCC
A tumour immune barrier (TIB) structure formed by the interaction of SPP1+ macrophages and cancer-associated fibroblasts (CAFs) appears to influence the efficacy of immunotherapy in patients with hepatocellular carcinoma (HCC), reveals a study.
Tumour immune barrier determines immunotherapy efficacy in HCC
01 Apr 2023Secukinumab yields sustained positive effects on molecular, histopathologic psoriasis markers
Treatment with secukinumab leads to sustained clinical response among patients with psoriasis, with clinical response being associated with rapid and persistent normalization of keratin 16 (K16) and inflammatory gene expression for most patients, according to data from the ObePso-S study.